{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:06:16Z","timestamp":1781766376544,"version":"3.54.5"},"reference-count":47,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Polish National Science Centre","doi-asserted-by":"crossref","award":["2021\/41\/B\/NZ5\/04397"],"award-info":[{"award-number":["2021\/41\/B\/NZ5\/04397"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Myelodysplastic syndromes\/neoplasms (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis, cytopenias, and a variable risk of progression to secondary acute myeloid leukemia (sAML). Despite major advances in the molecular and clinical characterization of MDS, mechanistic and translational research remains constrained by the limited availability of well-validated in vitro models. Many historically used cell lines are difficult to maintain, exhibit restricted proliferative capacity, or represent advanced disease stages rather than bona fide MDS, while others have been affected by misidentification or cross-contamination. This review provides a comprehensive and critical overview of currently available MDS and MDS-related cell lines, including MDS92, MDS-L and its sublines, M-TAT, TER-3, SKK-1, SKM-1, and MOLM-17\/18. We summarize their clinical origin, cytogenetic and molecular features, growth factor dependence, differentiation capacity, and experimental applications, with particular emphasis on their relevance to disease stage, clonal evolution, and leukemic transformation. In addition, we discuss the controversy surrounding misidentified models such as PC-MDS and highlight the importance of rigorous cell line authentication.<\/jats:p>","DOI":"10.3390\/ijms27020898","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:08:21Z","timestamp":1768550901000},"page":"898","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cell Lines in Myelodysplastic Syndromes\/Neoplasms (MDS) Research: A Review of Existing Models and Their Applications"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4006-5656","authenticated-orcid":false,"given":"Karolina","family":"Ma\u015bli\u0144ska-Gromadka","sequence":"first","affiliation":[{"name":"Department of Molecular Biology, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, 05-552 Magdalenka, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0399-5280","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Palusi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, 05-552 Magdalenka, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0631-4846","authenticated-orcid":false,"given":"Julia Weronika","family":"\u0141uczak","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, 05-552 Magdalenka, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8669-3359","authenticated-orcid":false,"given":"Rafa\u0142","family":"Skopek","sequence":"additional","affiliation":[{"name":"Department of Human Physiology and Pathophysiology, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, 01-938 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Kraj","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, 05-552 Magdalenka, Poland"},{"name":"Department of Oncology, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3430-5876","authenticated-orcid":false,"given":"Tino","family":"Schenk","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Clinic of Internal Medicine II, Jena University Hospital, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Zelent","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, 05-552 Magdalenka, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0148-541X","authenticated-orcid":false,"given":"\u0141ukasz","family":"Szyma\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, 05-552 Magdalenka, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/j.seminhematol.2024.09.007","article-title":"Understanding MDS Stem Cells: Advances and Limitations","volume":"61","author":"Patel","year":"2024","journal-title":"Semin. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/PPO.0000000000000665","article-title":"Epidemiology and Pathogenesis of Myelodysplastic Syndrome","volume":"29","author":"Rotter","year":"2023","journal-title":"Cancer J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s10147-019-01462-6","article-title":"Genetic Abnormalities and Pathophysiology of MDS","volume":"24","author":"Hosono","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41375-024-02181-2","article-title":"The Evolution of Preclinical Models for Myelodysplastic Neoplasms","volume":"38","author":"Mina","year":"2024","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood-2018-10-844670","article-title":"MDS Overlap Disorders and Diagnostic Boundaries","volume":"133","author":"Tanaka","year":"2019","journal-title":"Blood"},{"key":"ref_6","unstructured":"Hata, T., and Tomonaga, M. (2008). Hypocellular Myelodysplastic Syndrome: Relationship to Aplastic Anemia and Hypocellular Acute Myeloid Leukemia. Myelodysplastic Syndromes, CRC Press."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1309\/EWKEBC48R8KYETR3","article-title":"Clinical Significance of Cytogenetics in Myelodysplastic Syndromes","volume":"39","author":"Haddad","year":"2008","journal-title":"Lab. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/MPH.0000000000001763","article-title":"Reduction of Extramedullary Complications in Patients with Acute Myeloid Leukemia\/Myelodysplastic Syndrome Treated with Azacitidine","volume":"42","author":"Shabanova","year":"2020","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ambinder, A.J., and DeZern, A.E. (2022). Navigating the Contested Borders between Myelodysplastic Syndrome and Acute Myeloid Leukemia. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1033534"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/his.15353","article-title":"Future Directions in Myelodysplastic Syndromes\/Neoplasms and Acute Myeloid Leukaemia Classification: From Blast Counts to Biology","volume":"86","author":"Bewersdorf","year":"2025","journal-title":"Histopathology"},{"key":"ref_11","unstructured":"Roudot, H., and Fenaux, P. (2010). Myelodysplastic Syndromes and Myelodysplastic\/Myeloproliferative Neoplasms. Diagnostic Techniques in Hematological Malignancies, Cambridge University Press."},{"key":"ref_12","first-page":"335","article-title":"The Evaluation of the Outcome in Myelodysplastic Patients by Using Non-Cytogenetic Prognostic Scores","volume":"7","author":"Bumbea","year":"2014","journal-title":"J. Med. Life"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Steensma, D. (2008). Myelodysplastic Syndromes: Pathobiology and Clinical Management, CRC Press.","DOI":"10.3109\/9781420074406"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kubasch, A., and Platzbecker, U. (2023). Treatment Algorithm of Myelodysplastic Syndromes. Pathogenesis and Treatment of Leukemia, Springer Nature.","DOI":"10.1007\/978-981-99-3810-0_31"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1016\/j.clml.2021.01.024","article-title":"Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-Analysis","volume":"21","author":"Liu","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/hematology.2023000420","article-title":"How to Classify Risk Based on Clinical and Molecular Modeling: Integrating Molecular Markers in the Risk Assessment of Myelodysplastic Syndrome","volume":"2023","author":"Xian","year":"2023","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_17","first-page":"166","article-title":"The WHO Classification of the Myelodysplastic Syndromes","volume":"26","author":"Bain","year":"2004","journal-title":"Exp. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.mpmed.2008.12.003","article-title":"Myelodysplastic Disorders","volume":"37","author":"Killick","year":"2009","journal-title":"Medicine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12032-007-0031-y","article-title":"The Cell Growth, Morphology and Immunocytochemistry of Novel Cell Line Established from a Bone Marrow of the Patient with Therapy-Related Myelodysplastic Syndrome, Entitled PC-MDS","volume":"24","author":"Jakimov","year":"2007","journal-title":"Med. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/jcb.21770","article-title":"Advances in the Treatment of Acute Myeloid Leukemia: From Chromosomal Aberrations to Biologically Targeted Therapy","volume":"104","author":"Hofmann","year":"2008","journal-title":"J. Cell. Biochem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.leukres.2009.03.005","article-title":"Many Are Called MDS Cell Lines: One Is Chosen","volume":"33","author":"Drexler","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.1994.tb04904.x","article-title":"Establishment and Characterization of a Novel Myeloid Cell Line from the Bone Marrow of a Patient with the Myelodysplastic Syndrome","volume":"87","author":"Tohyama","year":"1994","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/leu.2013.372","article-title":"An MDS Xenograft Model Utilizing a Patient-Derived Cell Line","volume":"28","author":"Rhyasen","year":"2014","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1038\/s41375-018-0189-7","article-title":"An MDS-Derived Cell Line and a Series of Its Sublines Serve as an in Vitro Model for the Leukemic Evolution of MDS","volume":"32","author":"Kida","year":"2018","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13039-025-00714-7","article-title":"Integrated Cytogenetic and Genomic Profiling of the MDS-L Cell Line","volume":"18","author":"Mestre","year":"2025","journal-title":"Mol. Cytogenet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/jcp.10095","article-title":"New Human Myelodysplastic Cell Line, TER-3: G-CSF Specific Downregulation of Ca2+\/Calmodulin-Dependent Protein Kinase IV","volume":"191","author":"Mishima","year":"2002","journal-title":"J. Cell. Physiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/gcc.22430","article-title":"Immunophenotypic, Cytogenetic, and Mutational Characterization of Cell Lines Derived from Myelodysplastic Syndrome Patients after Progression to Acute Myeloid Leukemia","volume":"56","author":"Palau","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2141.1993.tb03334.x","article-title":"Establishment of a Leukaemic Cell Line from a Patient with Acquisition of Chromosomal Abnormalities during Disease Progression in Myelodysplastic Syndrome","volume":"85","author":"Nakagawa","year":"1993","journal-title":"Br. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.leukres.2004.11.024","article-title":"Acute Myeloid Leukemia Cell Lines MOLM-17 and MOLM-18 Derived from Patient with Advanced Myelodysplastic Syndromes","volume":"29","author":"Matsuo","year":"2005","journal-title":"Leuk. Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Skopek, R., Palusi\u0144ska, M., Kaczor-Keller, K., Pingwara, R., Papierniak-Wygl\u0105da\u0142a, A., Schenk, T., Lewicki, S., Zelent, A., Szyma\u0144ski, \u0141., and Skopek, R. (2023). Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065377"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"77436","DOI":"10.18632\/oncotarget.20497","article-title":"Oxidative Stress-Induced JNK\/AP-1 Signaling Is a Major Pathway Involved in Selective Apoptosis of Myelodysplastic Syndrome Cells by Withaferin-A","volume":"8","author":"Oben","year":"2017","journal-title":"Oncotarget"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3324\/haematol.2022.281444","article-title":"CCRL2 Affects the Sensitivity of Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia Cells to Azacitidine","volume":"108","author":"Karantanos","year":"2023","journal-title":"Haematologica"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-020-00362-7","article-title":"FBXO11 Is a Candidate Tumor Suppressor in the Leukemic Transformation of Myelodysplastic Syndrome","volume":"10","author":"Schieber","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/cas.12605","article-title":"Rigosertib Induces Cell Death of a Myelodysplastic Syndrome-Derived Cell Line by DNA Damage-Induced G2\/M Arrest","volume":"106","author":"Hyoda","year":"2015","journal-title":"Cancer Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bjh.17372","article-title":"Preclinical Characterisation and Development of a Novel Myelodysplastic Syndrome-Derived Cell Line","volume":"193","author":"Shafiee","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"27700","DOI":"10.1016\/S0021-9258(18)47042-1","article-title":"Erythropoietin-Dependent Induction of Hemoglobin Synthesis in a Cytokine-Dependent Cell Line M-TAT","volume":"269","author":"Minegishi","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-015-0312-6","article-title":"Drug Sensitivity in Cancer Cell Lines Is Not Tissue-Specific","volume":"14","author":"Jaeger","year":"2015","journal-title":"Mol. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.18632\/oncotarget.2024","article-title":"Phenotypic and Genotypic Characterization of Azacitidine-Sensitive and Resistant SKM1 Myeloid Cell Lines","volume":"5","author":"Cluzeau","year":"2014","journal-title":"Oncotarget"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.3892\/mmr.2015.4252","article-title":"Fucoidan Inhibits Proliferation of the SKM-1 Acute Myeloid Leukaemia Cell Line via the Activation of Apoptotic Pathways and Production of Reactive Oxygen Species","volume":"12","author":"Wei","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3109\/10428199509056841","article-title":"The SKM-1 Leukemic Cell Line Established from a Patient with Progression to Myelomonocytic Leukemia in Myelodysplastic Syndrome (MDS)-Contribution to Better Understanding of MDS","volume":"17","author":"Nakagawa","year":"1995","journal-title":"Leuk. Lymphoma"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3892\/ol.2020.11607","article-title":"SPAG6 Silencing Induces Autophagic Cell Death in SKM-1 Cells via the AMPK\/mTOR\/ULK1 Signaling Pathway","volume":"20","author":"Zhang","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3892\/ijo.2014.2768","article-title":"SPAG6 Silencing Inhibits the Growth of the Malignant Myeloid Cell Lines SKM-1 and K562 via Activating P53 and Caspase Activation-Dependent Apoptosis","volume":"46","author":"Yang","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"109736","DOI":"10.1016\/j.biopha.2019.109736","article-title":"4-Amino-2-Trifluoromethyl-Phenyl Retinate Induced Differentiation of Human Myelodysplastic Syndromes SKM-1 Cell Lines by up-Regulating DDX23","volume":"123","author":"Wang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.leukres.2007.01.012","article-title":"Characteristics of Novel Myeloid Precursor Cell Line, PC-MDS, Established from a Bone Marrow of the Patient with Therapy-Related Myelodysplastic Syndrome","volume":"31","author":"Kraguljac","year":"2007","journal-title":"Leuk. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/mc.23189","article-title":"Contaminated and Misidentified Cell Lines Commonly Use in Cancer Research","volume":"59","author":"Cheung","year":"2020","journal-title":"Mol. Carcinog."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Fusenig, N.E., Capes-Davis, A., Bianchini, F., Sundell, S., and Lichter, P. (2017). The Need for a Worldwide Consensus for Cell Line Authentication: Experience Implementing a Mandatory Requirement at the International Journal of Cancer. PLoS Biol., 15.","DOI":"10.1371\/journal.pbio.2001438"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/2\/898\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T05:11:38Z","timestamp":1768713098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/2\/898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["ijms27020898"],"URL":"https:\/\/doi.org\/10.3390\/ijms27020898","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]}}}